Background: Safety and efficacy of gemcitabine plus docetaxel (GD) and capecitabine plus docetaxel (CD) were compared in patients with metastatic breast cancer, where the alternate crossover monotherapy (GD/C or CD/G) was predetermined.
introduction Despite significant improvements in survival outcomes over the past two decades, breast cancer remains the most common malignancy among women and the second leading cause of cancer deaths in the United States [1] . For patients with metastatic breast cancer (MBC), long-term prognosis remains poor, especially for patients with hormone unresponsive or refractory disease. For these patients, chemotherapy can prolong survival, provide palliative care, and improve quality of life [2, 3] . While a wide variety of therapeutic agents and combinations are currently utilized for MBC patients, there remains a need for new treatment options.
A number of chemotherapy agents, including capecitabine, gemcitabine, and docetaxel, have proven efficacy as single agents in anthracycline-pretreated patients with MBC [4] [5] [6] [7] [8] [9] . Also, certain taxane-based combination regimens have shown improvements in efficacy compared with single agents alone. For example, the combinations of gemcitabine plus paclitaxel and capecitabine plus docetaxel (CD) both showed improved time to disease progression (TtP), overall response rate (ORR), and overall survival (OS) compared with single-agent taxanes as first-line treatment of MBC after prior anthracycline therapy original article [10, 11] . In addition, a recent phase III trial comparing CD with the combination of gemcitabine plus docetaxel (GD) reported nearly identical efficacy for each combination regimen in anthracycline-pretreated patients with MBC [12] . All these trials evaluated combination regimens against either single agents or other combination regimens. Few large, randomized phase III trials have examined planned crossover chemotherapy strategies in MBC [13] [14] [15] . The current trial compared safety and efficacy of GD and CD regimens in patients with first-or second-line MBC where the alternate crossover monotherapy (GD/C or CD/G) was predetermined.
patients and methods
The primary end point of this international, multicenter, open-label, randomized phase III trial was TtP. Secondary end points included evaluation of drug-related adverse events (AEs), ORR, and OS. This study complied with the principles of Good Clinical Practice and the Declaration of Helsinki. Institutional review boards approved the protocol and patients provided written informed consent before enrollment.
patient eligibility
Enrolled patients were ‡18 years old with histologically or cytologically confirmed locally advanced or metastatic disease, life expectancy ‡12 weeks, Eastern Cooperative Oncology Group (ECOG) performance status (PS) of one or less, and adequate renal, hepatic, and bone marrow function. Patients may have completed neoadjuvant or adjuvant taxane therapy ‡6 months before enrollment, prior anthracycline, hormone, or immunotherapy and no more than one prior line of chemotherapy for MBC. Radiation therapy to <25% of bone marrow was allowed ‡4 weeks before enrollment, provided patients had recovered from all side-effects. Exclusion criteria included prior taxane therapy for MBC, prior therapy with gemcitabine or capecitabine, ongoing concomitant trastuzumab therapy, or brain metastasis.
treatment plan
Patients assigned to the GD arm received gemcitabine 1000 mg/m 2 by i.v.
infusion over 30 min on days 1 and 8 and i.v. docetaxel 75 mg/m 2 over 1 h on day 1. Docetaxel was administered before gemcitabine on day 1. Patients assigned to the CD arm received i.v. docetaxel 75 mg/m 2 over 1 h on day 1 and oral capecitabine 1000 mg/m 2 twice daily on days 1 through 14.
Treatment cycles were repeated every 3 weeks for both induction arms until patients experienced disease progression (PD). Treatment cycles could also be altered or stopped based upon observed AEs, patient request, or investigator decision. All patients receiving docetaxel were premedicated with 8 mg dexamethasone, given orally twice daily for 3 days, starting 1 day before docetaxel administration. Patients who progressed on induction GD or CD were started on regimens of single-agent capecitabine or gemcitabine, respectively, according to induction dosing schedules within 4 weeks of documented PD. Patients experiencing grades 3-4 hematologic or nonhematologic AEs (except nausea/vomiting and alopecia) had their gemcitabine dose reduced by 25% or omitted based upon physician discretion. Patients who had any grade 2 neuropathy, grade 4 thrombocytopenia, or grade 4 neutropenia with fever or for >7 days had their docetaxel dose reduced by 25%. Patients with any grades 3-4 nonhematologic AE had their docetaxel dose held and then reduced by 25% in subsequent cycles if toxicity was resolved to grade 1 or less. Patients who experienced any grades 2-4 hand-foot syndrome (HFS) had their capecitabine dose held or reduced by up to 50% until toxicity was resolved to grade 1 or less. Capecitabine therapy could be discontinued with any grade 4 HFS at physician discretion. Use of granulocyte colony-stimulating factor (G-CSF), erythropoietin, and antiemetics was allowed.
patient evaluations
Medical history, physical examination, baseline evaluation of ECOG PS, comprehensive laboratory tests, and physical measurement of palpable lesions were completed £2 weeks before enrollment. Pretreatment radiologic assessments using either computed tomography (CT) scan or magnetic resonance imaging (MRI) scan of the chest were completed £28 days before enrollment and after every third cycle. CT scan or MRI scan of bone or brain was carried out if clinically indicated. Tumor response was evaluated using Response Evaluation Criteria in Solid Tumors [16] for measurable disease in combination with assessments of nonmeasurable disease. Confirmation scans were carried out 3-4 weeks (minimum 21 days) from the first evidence of response. AEs were assessed before each cycle using the National Cancer Institute-Common Toxicity Criteria, version 2.0 [17] .
statistical considerations
Patients were randomly assigned in a 1:1 ratio to the two induction arms. Patients receiving at least one treatment dose were included in the safety analysis. Efficacy analyses were conducted on the intent-to-treat population, which included all randomized patients. Time-to-event parameters were estimated from the date of randomization using the Kaplan-Meier method [18] and results for each treatment arm were compared by log-rank test [19] . All two-sided statistical comparisons between the treatment arms were judged relative to a significance level of a = 0.05. The Fisher's exact test was used to determine P values for comparisons of response rates and AEs. Confidence intervals (CIs) for all parameters were constructed at the 95% level.
Sample size calculation was based on the comparison of TtP between the two induction arms, using Freedman's method [20] . It was estimated that 442 patients (221 per arm) would be needed to obtain the 385 PD events required to observe a 2-month difference in TtP between treatment arms with 80% statistical power. As a post hoc exploratory analysis, TtP induction-crossover sum, measured from induction through crossover therapies, was calculated for only those patients who received single-agent crossover. Induction TtP was estimated for all patients from time of randomization to date of first PD. Crossover TtP was estimated for all crossover patients from time of first single-agent dose to date of further documented PD. The TtP induction-crossover sum was calculated by adding induction TtP to crossover TtP. The OS time was defined as the number of months between the date of randomization and the date of death due to any cause and was censored at the date of last contact for patients who were still alive. Time to treatment failure (TTF) was added as a post hoc analysis and was defined as the time from randomization to date of early discontinuation due to toxicity, first PD, or death from any cause. Baseline patient characteristics are summarized in Table 1 and were generally well balanced between arms. For all enrolled patients, 80.2% (n = 381/475) were £65 years old, 73.9% (n = 351/475) had an ECOG PS score of zero, 84.6% (n = 402/ 475) had measurable disease, 67.2% (n = 319/475) had visceraldominant disease, 88.2% (n = 419/475) were chemonaive for MBC, 56.6% (n = 269/475) had prior anthracycline therapy, and 56.6% (n = 269/475) of patient cancers were estrogen receptor positive. While information about prior treatment with an adjuvant taxane was not sufficiently captured during pretrial interviews, the data available revealed good balance between arms. Data regarding human epidermal growth factor receptor 2 (HER2) status were not captured. Twelve randomized patients (GD, n = 3; CD, n = 9) withdrew or were ineligible before treatment and were not included in the safety population. A total of 463 patients started induction therapy (GD, n = 236; CD, n = 227). In the GD arm, 138 patients discontinued for reasons other than PD; major reasons were AEs (n = 43), investigator decision (n = 40), and patient request (n = 38). There were two drug-related patient deaths (one due to multiorgan failure and the other due to respiratory distress syndrome) in the GD arm. In the CD arm, 144 patients discontinued for reasons other than PD; major reasons were AEs (n = 67), investigator decision (n = 31), and patient request (n = 27). Significantly, more (P = 0.009) CD patients (n = 67/ 236, 28.4%) discontinued due to AEs compared with GD patients (n = 43/239, 18.0%). There was one patient death in the CD arm due to acute bowel perforation that was unrelated to treatment.
A total of 156 patients (33.7% of the safety population, n = 463) received crossover monotherapy; 76 GD/C patients and 80 CD/G patients. Two patients, one in each crossover arm, withdrew before starting treatment and were not included in the TtP analyses for crossover therapies. Baseline characteristics for crossover patients were generally well balanced between arms and were similar to baseline characteristics for patients before induction therapies. The discontinuation profile was similar in both crossover arms, with PD as the major reason for discontinuation (GD/C, n = 50/77, 64.9%; CD/G, n = 53/81, 65.4%).
For patients not assigned to crossover therapy, 30.9% of GD patients (n = 50/162) and 34.2% of CD patients (n = 53/155) received some form of poststudy treatment. The most common poststudy treatments included hormonal therapy (GD, n = 29; CD, n = 21), docetaxel (GD, n = 14; CD, n = 12), gemcitabine (GD, n = 4; CD, n = 12), and capecitabine (GD, n = 9; CD, n = 4).
efficacy
A total of 398 patients with measurable disease were assessable for response to induction therapy; 34.8% of patients (n = 72/ 207) responded to GD and 40.8% (n = 78/191) responded to CD, a nonsignificant difference (P = 0.239). A total of 142 crossover patients were assessable for response; 15.3% (n = 11/ 72) who crossed over after GD responded to capecitabine, whereas 7.1% (n = 5/70) who crossed over after CD responded to gemcitabine. This difference was not statistically significant (P = 0.185).
Despite over-accrual of patients, censoring due to discontinuations resulted in only 324 TtP events compared with the 385 events planned before trial initiation. Median follow-up time was 19.6 months for GD patients and 20.6 months for CD patients. There was no statistically significant difference [hazard ratio (HR) = 1.101, 95% CI 0.885-1.370, P = 0.387] in TtP between the GD (9.3 months) and CD (8.9 months) induction arms (Figure 2A ). Median TtP during crossover therapy ( Figure 2B ) was greater for GD/C patients (4.5 months) compared with CD/G patients (2.3 months), but the difference was not significant (HR = 0.777, 95% CI 0.552-1.094, P = 0.149). original article
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In an exploratory analysis (see Figure 2C and D), the median TtP during induction for GD/C crossover patients (6.7 months) was greater than for CD/G crossover patients (4.6 months), but the difference was not significant (HR = 0.786, 95% CI 0.570-1.083, P = 0.140). The median TtP induction-crossover sum was 5.1 months greater for GD/C Patients were also evaluated for TTF and OS. The median TTF for GD induction was 6.7 months (95% CI 6.2-8.3) and was 5.1 months (95% CI 4.4-6.2) for CD (P = 0.784). Figure 3 shows OS curves that are virtually superimposable (HR = 1.031, 95% CI 0.830-1.280, P = 0.785) with median OS of 23.0 months in the GD arm and 23.3 months in the CD arm. Consistent with TtP results, the GD/C crossover group had greater median OS (n = 77, 25.1 months, 95% CI 18.9-30.4) compared with the CD/G group (n = 81, 18.7 months, 95% CI 15.0-24.3). However, comparison of OS for crossover groups was not statistically significant (P = 0.296). Table 2 summarizes drug administration results. Total, mean, and median numbers of cycles received were similar in each induction arm and were also similar comparing crossover treatment groups. Patients received a median of six induction cycles and three cycles of crossover monotherapy. Dose adjustment rates and the relative dose intensities for each drug were similar in both induction arms as well as for gemcitabine and capecitabine administered after crossover. However, dose adjustment rates for capecitabine and gemcitabine were considerably greater in combination with docetaxel during induction than as single agents during crossover. Higher dose intensities for capecitabine and gemcitabine observed during crossover were consistent with these results. Table 3 summarizes drug-related AE results. During induction, GD produced significantly more grades 3-4 fatigue, elevated ALT/AST, neutropenia, leukopenia, and thrombocytopenia compared with CD. However, rates of febrile neutropenia were similar. Patients receiving GD had a higher rate of treatment with G-CSF (n = 110/236, 46.6%) compared with CD patients (n = 60/227, 26.4%), which was consistent with greater neutropenia observed for GD. CD produced significantly more grades 3-4 HFS, nausea/vomiting, and mucositis compared with GD. During crossover (D) Crossover patients, sum-induction-crossover phases. TtP for induction was censored at the earliest of the following: death date due to reason rather than metastatic breast cancer (MBC), the last contact date, the start date of new antitumor treatment, or the first dose date of crossover stage. TtP for crossover was censored at the earliest of the following: death date due to reason rather than MBC, the last contact date, or the start date of new antitumor treatment. GD, gemcitabine-docetaxel; CD, capecitabine-docetaxel; GD/C, gemcitabine-docetaxel to capecitabine; CD/G, capecitabine-docetaxel to gemcitabine; CI, confidence interval; N, number of patients; n, number in group; P, P value.
drug administration and toxicity
original article Annals of Oncology monotherapy, capecitabine produced significantly greater grades 2-4 diarrhea, while gemcitabine produced significantly greater neutropenia.
discussion
The decision to treat MBC patients with single-agent, sequential, or combination regimens continues to be debated [21] . Combination therapies often achieve higher response rates, which may be a significant result for patients with rapidly progressing or symptomatic disease, as long as the response can be achieved without unacceptable toxic effects. In the current trial, we not only compared two combination regimens (CD and GD) with established efficacy in patients with MBC but we also evaluated the safety and efficacy of sequential treatment with predetermined crossover monotherapies (GD/C or CD/G) for patients who progressed after induction. Our results showed expected differences in toxicity profiles and no statistically significant differences in efficacy between the crossover sequences. However, the toxicity discontinuation profiles for induction therapy and the exploratory analyses for the TtP induction-crossover sum suggest that further investigation of the GD/C crossover regimen as a preferred combination sequence for certain MBC patients may be warranted.
Both GD and CD combination regimens have been previously evaluated in the treatment of MBC [10, [22] [23] [24] [25] [26] [27] . Toxicity results for the GD and CD induction regimens in the current trial were generally similar to previous clinical reports. A recently published phase III trial by Chan et al. [12] compared CD with GD in anthracycline-pretreated patients with MBC. The GD regimen in the Chan trial was identical to the regimen used in this report. However, the CD regimen delivered capecitabine at the Food and Drug Administration recommended dose of 1250 mg/m 2 compared with the lower community standard dose of 1000 mg/m 2 utilized in our trial. Overall survival. GD, gemcitabine-docetaxel; CD, capecitabine-docetaxel; CI, confidence interval; N, number of patients; n, number in group; OS, overall survival; P, P value. The lower capecitabine dose used here is consistent with the lower incidence of neutropenia (30.5% versus 78.6%), febrile neutropenia (6.2% versus 14.7%), and mucositis (4.4% versus 15.3%) and with the higher capecitabine dose intensity (77.4% versus 57.7%) observed in the current trial compared with the Chan trial. Despite these differences, toxicity-related discontinuations in the CD arm (28.4%) were significantly greater (P = 0.009) than in the GD arm (18.0%), a result fully consistent with toxicity-related discontinuations observed in the Chan trial (CD = 29.3%, GD = 13.8%).
Efficacy data in the current trial were also generally consistent with the Chan results. In both trials, there were no statistically significant differences in ORR and OS observed between CD and GD arms. While not completely equivalent in terms of time to event definition, the progression-free survival (PFS) results observed in Chan et al. and the TtP results observed here were also not statistically different when comparing CD and GD regimens in each study. In addition, the relative values for ORR, progression (PFS or TtP), and OS were very similar for the CD and GD regimens in both trials, suggesting equivalent efficacy for each study. The Chan trial reported a trend (P = 0.059) toward improved TTF for the GD arm, possibly due to greater toxicity-related treatment discontinuations with CD. In the current trial, median TTF was also greater for GD compared with CD but was not statistically different. The shorter TTF interval observed with CD is partly due to the higher rate of discontinuations due to HFS, despite the lower capecitabine dose used in this trial.
As mentioned previously, TtP was not significantly different comparing CD and GD induction regimens. In a post hoc analysis designed to explore the possible impact of regimen sequence on efficacy, the TtP induction-crossover sum, measured from induction through crossover therapies, was 5.1 months greater for GD/C crossover than for CD/G crossover but did not reach statistical significance (P = 0.093). Further analysis showed that both induction GD and singleagent capecitabine regimens contributed to the greater median TtP induction-crossover sum observed in the GD/C crossover group (see Figure 2B and C). Baseline patient demographics of both crossover groups were very similar to baseline results for all randomized patients before induction therapies, suggesting that the difference in TtP inductioncrossover sum between crossover groups was not likely influenced by any particular patient characteristic amplified by progression. However, it should be mentioned that HER2 receptor status and anti-HER2 therapy data were not adequately collected during this trial and it is recognized that these could be confounding factors in this analysis.
Keeping in mind the limitations of this exploratory analysis, the TtP induction-crossover sum results suggest the possibility that GD followed by single-agent capecitabine might be a preferred sequence option for MBC patients who are logical candidates for combination therapy. This proposition is supported by the toxicity data, which suggests that capecitabine was better tolerated as a single agent in this trial. Based upon poststudy chemotherapy analysis, Chan et al. [12] have also original article Annals of Oncology suggested the possibility that the sequence of GD followed by single-agent capecitabine may provide a therapeutic opportunity in clinical practice for long-term treatment of MBC. However, the preferred use of the GD/C crossover sequence in the treatment of MBC patients remains investigational and will require additional study. Another important trial observation was that only about one-third of patients in each induction arm (34.3% in CD; 32.2% in GD) received crossover therapy. This crossover rate was lower than the modest crossover rates (50%-53%) reported in previous phase III MBC trials with planned crossover [13] [14] [15] . Aside from PD, discontinuations during induction therapy in the current trial accounted for 53.1% of all treated patients. Follow-up showed that roughly one-third of these 'noncrossover' patients in each induction arm received some poststudy treatment. These results illustrate the practical limitations of trial designs involving the use of predetermined sequential therapies when many viable therapy options are available for the treatment of MBC. 
